Suzhou Municipal Key Laboratory of Cancer Biology and Chronic Diseases

Overview

The Suzhou Municipal Key Laboratory of Cancer Biology and Chronic Diseases is dedicated to advancing the understanding of cancer and chronic diseases. Established in 2024, the laboratory functions as an interdisciplinary hub, uniting leading scientists from the School of Science, the University, and the local biotech and biopharmaceutical industries. Our research encompasses a broad spectrum of areas, including cancer biology, genetic and epigenetic modifications associated with cancer, cancer immunotherapy, and chronic diseases such as reproductive health, aging, and neurodegenerative disorders. We also focus on precision medicine and bioinformatics.

In addition to our research initiatives, we are deeply committed to education and training. We actively cultivate the next generation of scientists through mentorship programs, internships, and workshops, fostering a diverse and dedicated community of researchers with a shared mission to combat cancer and chronic diseases. Our interdisciplinary approach, cutting-edge research, and dedication to excellence position the Suzhou Key Laboratory as a significant contributor to advancements in biomedical research and healthcare.

Research Themes

The laboratory’s research is organized into several key themes, each addressing critical aspects of cancer and chronic disease:

• Cancer Biology, Genetics, and Epigenetics
• Cancer Immunotherapy
• Chronic Conditions such as Reproductive Health, Aging, and Neurodegenerative Disorders
• Precision Medicine and Computational Biology

This comprehensive approach enables the Suzhou Key Laboratory to address the multifaceted challenges posed by these complex diseases from multiple perspectives.

Research Projects

1. Role of Cellular mRNA Methylation Mediated by Viruses or Viral Proteins in Carcinogenesis
   Lead PI: Dr. Rong Rong
   This research explores the emerging field of epitranscriptomics, particularly the role of viral-mediated mRNA methylation in carcinogenesis. Although still in its early stages, growing evidence suggests that these methylation processes may significantly influence cellular activities relevant to cancer development.
2. G Protein-Coupled Receptors (GPCRs) in Cancer and Chronic Diseases
   Lead PI: Professor Zhiliang Lu
   GPCRs are pivotal in regulating various physiological processes, including cell proliferation, migration, survival, and differentiation. Dysregulation of GPCR signaling has been linked to cancers and chronic diseases such as metabolic disorders and inflammation. This project focuses on understanding the complex interplay between GPCR signaling and disease progression, also with an emphasis on the role of G protein signaling in mRNA methylation during cancer transformation.
3. Bioinformatics Analyses of RNA Modifications during Carcinogenesis
   Lead PI: Professor Jia Meng
   This project leverages bioinformatics to analyze RNA modifications, such as N6-methyladenosine (m6A) and 5-methylcytosine (m5C), to better understand their role in cancer development and progression. Insights gained may lead to novel therapeutic targets for cancer treatment.
4. Neurodegenerative Diseases
   Lead PI: Dr. Lee Wei Lim
   This research focuses on unraveling the molecular mechanisms underlying neurodegenerative diseases, to develop therapeutic interventions.
5. Epigenetic Reprogramming for Reversing Age-Related Diseases
   Lead PI: Dr. Yong Shen
   Aging is associated with biological changes that impair cellular function and contribute to chronic diseases like cardiovascular and neurodegenerative disorders. This project explores the potential of epigenetic reprogramming, particularly through the activation of endogenous OSK genes using CRISPR technology, to restore cellular functions and promote healthy aging.
6. Functional Manipulation of the Endoplasmic Reticulum (ER) by Engineered ER Chimeric Microproteins
   Lead PI: Dr. Kozo Hamada
   The ER plays a crucial role in protein folding and is implicated in various diseases when dysregulated. This project aims to develop and study ER-resident microproteins with the potential to manipulate ER functions, offering new avenues for therapeutic interventions.
7. AI and Molecular Modeling-Based Drug Design for Therapeutics
   Lead PI: Dr. Chun Chan and Professor Zhiliang Lu
   This theme focuses on utilizing artificial intelligence and molecular modelling to design new therapeutic drugs, particularly targeting cancer and chronic diseases.
8. Cancer Precision Diagnosis and Medicine
   Lead PIs: Drs. Rong Rong, Jia Meng, Yong Shen, and Zhiliang Lu (in collaboration with Suzhou Sano Precision Medicine Ltd.)
   This research aims to tailor cancer diagnosis and treatment strategies to individual patients by leveraging advanced molecular and computational techniques to identify novel gene mutations linked to cancer.

Mission & Objectives

The Suzhou Key Laboratory was established with the vision of addressing the critical challenges posed by cancer and chronic diseases. Equipped with state-of-the-art technologies and facilities, our research spans fundamental studies of disease mechanisms to translational research with real-world applications. A primary objective is to foster a dynamic research environment that encourages innovation and creativity. Through collaborative projects with academic institutions, hospitals, and industry stakeholders, we aim to accelerate scientific discoveries and advance therapeutic interventions.

Significance

The Suzhou Municipal Key Laboratory of Cancer Biology and Chronic Diseases stands as a beacon of innovation and collaboration in biomedical research. Aligned with the School of Science and Xi’an Jiaotong-Liverpool University’s research plans, the laboratory is committed to advancing scientific knowledge, promoting interdisciplinary collaboration, and addressing global health challenges. Additionally, our commitment to education, training, and global engagement underscores our dedication to excellence and impactful research.

Director and Principal Investigators

• Professor Zhiliang Lu (Director)
• Professor Jia Meng
• Dr. Rong Rong
• Dr. Lee Wei Lim
• Dr. Yong Shen
• Dr. Kozo Hamada
• Dr. Chun Chan

Selected Outcomes

Publications

• Feng, Y., et al. (2024). “CD39+ Tumor-Infiltrating T Cells from Colorectal Cancers Exhibit Dysfunctional Phenotype.” American Journal of Cancer Research, 14, 585-600.
• Liu, S., et al. (2024). “Low Iodine Nutrition Knowledge in Chinese Breastfeeding Women despite Adequate Iodine Status.” Nutrients, 16, 491-505.
• Liu, S., et al. (2024). “Breast Milk Iodine Concentration in Early Lactation as a Biomarker of Iodine Status in Breastfeeding Women.” British Journal of Nutrition, 131, 286-295.
• Sivasudhan, E., et al. (2024). “RNA Modifications in Handbook of Molecular Biotechnology.” 1st ed. Taylor and Francis.

Patents

• Lu, Z., Shen, L., Meng, J., & Rong, R. (2024). “NanoBRET Receptor-Binding Drug Screening System Based on Cy5-Labeled Ligands.” Patent No. CN 112575052 B.

Funds

Future Directions

The Suzhou Municipal Key Laboratory of Cancer Biology and Chronic Diseases remains committed to excellence and innovation in the fight against these diseases. Looking ahead, we aim to expand our research reach and impact, continuing to make significant contributions to global health.